US-12616669-B2 - Methods and chemical compositions for treating skin conditions by providing long lasting skin pH control for improving skin barrier function

Abstract

Provided are methods and composition for treating skin barrier functions and associated disorders. Formulated compositions may be applied on human skin to maintain a desired skin surface pH over an extended period of time without irritating the skin. Maintaining the desired surface pH aids in treatment of eczema, in addition to other skin conditions.

Inventors

• Rafal M. Pielak

Assignees

• SOTERI SKIN, INC.

Dates

Publication Date

20260505

Application Date

20250827

Claims (7)

1. 1 . A composition for treating atopic dermatitis in a target skin area comprising: citric acid and sodium citrate comprising 0.3-15% weight of the composition, gluconic acid comprising 0.1-1.0% weight of the composition, glutamic acid comprising 0.1-1.0% weight of the composition, aspartic acid comprising 0.1-1.0% weight of the composition, and histidine comprising 0.1-2.0% weight of the composition, shea butter comprising 8.5-8.7% weight of the composition, the shea butter comprising: oleic acid, stearic acid, palmitic acid, and linoleic acid; free fatty acid content of 1% weight of the composition, sunflower oil comprising 6.5% weight of the composition, the sunflower oil comprising linoleic acid, and free fatty acid content of 1 percent; and an amino acid, peptide mix, or combination thereof, comprising 0.1-5% weight of the composition; wherein the composition maintains the pH of a target skin area between 4.2 and 5.0.
2. 2 . The composition of claim 1 , wherein the target skin area comprising surface of the skin currently is or previously was affected by eczema symptoms comprising surface of the skin currently or previously indicating the eczema symptoms including one or more of: redness; itching; inflammation; dryness; and scaling.
3. 3 . The composition of claim 1 , wherein the composition is capable of maintaining the pH buffer for at least six hours.
4. 4 . The composition of claim 1 , wherein the composition further comprises: niacinamide in an amount of 0.5-2% weight; colloidal oatmeal in an amount of 0.5-5.0-% weight; glycerin in an amount of 5.0-8.0% weight; and a skin mimicking ceramide complex in an amount of 0.1-5.0% weight.
5. 5 . The composition of claim 4 , wherein the composition further comprises a solvent in an amount of 53 to 54 weight percentage of the composition.
6. 6 . The composition of claim 5 , wherein the solvent comprises purified water.
7. 7 . The composition of claim 6 , wherein the composition further comprises: niacinamide in an amount of 0.5-2% weight of the composition; colloidal oatmeal in an amount of 0.5-5.0% weight of the composition; glycerin in an amount of 5.0-8.0% by weight of the composition; and a skin mimicking ceramide complex in an amount of 0.1-5.0% weight of the composition.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. patent application Ser. No. 19/306,366, filed on Aug. 21, 2025, which is a continuation of U.S. patent application Ser. No. 19/091,737, filed on Mar. 26, 2025, which claims priority from U.S. Provisional Patent Application No. 63/766,313, filed Mar. 3, 2025, entitled “Chemical Composition Providing Long Lasting Skin pH Control for Improving Skin Barrier Function and Treatment of Skin Barrier Disorders,” and is a continuation-in-part of U.S. patent application Ser. No. 18/253,173, filed May 16, 2023, entitled “Chemical Composition Providing Long Lasting Skin pH Control for Improving Skin Barrier Function and Treatment of Skin Barrier Disorders”, which is nation stage filing of PCT/US22/71895 filed Apr. 25, 2022, entitled “Chemical Composition Providing Long Lasting Skin pH Control for Improving Skin Barrier Function and Treatment of Skin Barrier Disorders”, which claims priority to both U.S. Provisional Patent Application No. 63/299,239, filed Jan. 13, 2022, and U.S. Provisional Patent Application No. 63/179,998, filed Apr. 26, 2021, and additionally claims priority from U.S. Provisional Patent Application No. 63/766,313, filed Mar. 3, 2025, entitled “Chemical Composition Providing Long Lasting Skin pH Control for Improving Skin Barrier Function and Treatment of Skin Barrier Disorders.” which are all incorporated herein by reference in their entireties. FIELD The present disclosure relates generally to skin topical compositions and formulations, and more specifically to method of application of topical formulations and topical formulations designed to maintain optimal skin surface pH over an extended period of time. BACKGROUND The formation of lipophilic components of Stratum Corneum (SC) involves several pH-dependent enzymes. Two key lipid-processing enzymes, beta-glucocerebrosidase and acidic sphingomyelinase, have pH optima of 5.6 and 4.5, respectively. Both lipid-processing enzymes are involved in the synthesis of ceramides, which are critical components of the permeability barrier. Optimal skin surface pH does not only influence the barrier homeostasis, but also affects SC integrity, cohesion, and desquamation. An elevated pH increases the activity of serine proteases, kallikrein 5 and 7, which are involved in the desquamation and degradation of corneodesmosomes. Acidic pH is also essential for normal skin flora growth, whereas pathogenic bacteria, such as Staphylococcus aureus, thrives at a neutral pH level. A number of factors, including both endogenous and exogenous elements, affect skin pH. Various studies have shown that elevations of pH in normal skin create a disturbed barrier, linked to increased activity of serine proteases and reduced activities of ceramide-generating enzymes. Therefore, changes in skin pH greatly affect skin function and skin health, as well as contribute to a number of skin conditions, such as atopic dermatitis, eczema, rosacea, psoriasis, and acne. BRIEF SUMMARY This summary is intended to provide an overview of the subject matter of the present disclosure, and is not intended to identify essential elements or key elements of the subject matter, nor is it intended to be used to determine the scope of the claimed implementations. Its sole purpose is to present some concepts of one or more exemplary aspects in a simplified form as a prelude to the more detailed description that is presented later. The proper scope of the present disclosure may be ascertained from the claims set forth below in view of the detailed description below and the drawings. One or more exemplary embodiments describe an exemplary method for treating eczema, comprising maintaining a first pH buffer at a target skin area between 4.5 and 5.5 for a first period of time by applying a first composition to the target skin area, the first composition with a first buffer capacity concentration of acids and conjugate bases, the target skin area comprising surface of skin currently or previously indicating symptoms of eczema, the first period of time comprising at least five days, and wherein the applying the first composition comprising applying the first composition over the at least five days at least twice daily. In an exemplary embodiment, the first composition may comprise a first agent comprising citric acid, sodium citrate, or combination thereof, comprising 0.3-1.5% weight composition of the first composition, and comprising pKa of 3.13, 4.76, or 6.0, gluconic acid comprising 0.1-0.5% weight composition of the first composition, the gluconic acid comprising pKa of 3.7, glutamic acid comprising 0.1-0.5% weight composition of the first composition, the gluconic acid comprising pKa of 2.19 and 4.25, aspartic acid comprising 0.1-0.5% weight composition of the first composition, the gluconic acid comprising pKa of 1.88 and 3.65, and histidine comprising 0.1-2.0% weight composition of the first composition, the gluconic acid com